CO.DON AG: CO.DON AG launches new website

DGAP-News: CO.DON AG / Key word(s): Miscellaneous
03.02.2020 / 14:28
The issuer is solely responsible for the content of this announcement.

CO.DON AG launches new Website

Berlin / Teltow / Leipzig, 03 February 2020 - Today, CO.DON AG launched its new, redesigned website: target group-oriented, modern and precise - this is how the medium-sized biopharmaceutical company informs visitors on its website at www.codon.de.

The arrangement of the website's content into main subjects is a vital element of the new design. Professionals such as physicians as well as the interested public such as patients, investors, potential clients for cell cultivation and applicants will quickly find their way around the clear navigation. The desired information is only a few clicks away. The optimization for mobile devices ensures the website's user-friendliness and easy operation at all times.

A press portal with current announcements as well as a media section where images for journalists are provided complement the new website.

Tilmann Bur, Board of CO.DON AG: "A modern website for an innovative company - the production and application of cell-based pharmaceuticals have a high need for explanation, which we meet with our new website. We provide basic information in a comprehensible form and, thereby, give an insight into our business segment. In addition, on our new website, we emphasize our focus on the development of new markets and winning customers for our EU-wide approved product".

CO.DON AG develops, produces and distributes autologous cell therapies for the minimally invasive repair of cartilage defects. The product being marketed is a cell therapy product for the minimally invasive treatment of cartilage damage in the knee joint that uses only the patient's own cartilage cells ("autologous chondrocytes"). CO.DON's method is currently used in over 200 clinics in Germany and more than 15,000 patients have already been treated. In July 2017 CO.DON AG received central EU marketing authorisation for this product from the European Medicines Agency (EMA). At the Leipzig site, CO.DON has built one of the world's largest and most modern facilities for the production of human cells on an industrial scale for in-house and contract manufacturing. The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Tilmann Bur.

Further information is available from www.codon.de.

Contact

Matthias Meißner
Director Corporate Communications
Investor Relations / Public Relations
T: +49 (0)30-240352330
F: +49 (0)30-240352309
E: ir@codon.de

03.02.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de